Thereby, oncogenic expression of MYC has been shown to dampen the expression of activating NK cell receptors in high-risk neuroblastoma, indicating that MYC expression may serve as a biomarker for NK cell therapy [25]. This evidence concerns the gene MYC and neuroblastoma.